Canada Oncology Therapeutics Market Report 2022 to 2030

Canada Oncology Therapeutics Market Analysis

$ 3999

Canada's oncology therapeutics market is likely to grow at a CAGR of 8.4% from a market size of $14.53 Bn in 2022 to $27.7 Bn in 2030. The market is growing primarily due to the rise in cancer prevalence, population growth, and increased consumer knowledge of cancer therapies. Oncology drug market growth in Canada is anticipated to be constrained by the high development costs for new drugs, failure risk, and unfavourable side effects of anti-cancer drug therapy. This report is segmented by application, by drugs, by therapy, by route of administration, and by distribution channel. Some key players in this market include AstraZeneca, GlaxoSmithKline, Eli Lilly, Roche Diagnostics, Novartis, Pfizer, Merck, Gilead, Sanofi, Celgene Corporation, and others.

ID: IN10CAPH042 CATEGORY: Pharmaceuticals GEOGRAPHY: Canada AUTHOR: Dhruv Joshi

Buy Now

Canada Oncology Therapeutics Market Executive Summary

Canada's oncology therapeutics market is likely to grow at a CAGR of 8.4% from a market size of $14.53 Bn in 2022 to $27.7 Bn in 2030., exhibiting a CAGR of 8.4% during the forecast period 2022-2030. In 2023, the Canadian Cancer Society predicts that there will be 241,000 new instances of cancer diagnosed in the country. At 14% of all new cases, lung cancer is one of the most frequently diagnosed diseases in Canada. Around 30% of all fatalities in Canada are caused by cancer, making it the country's greatest killer. Around 25% of all cancer deaths in Canada are caused by lung cancer, which is the most common malignancy. Surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy are all possible forms of cancer treatment in Canada. The type of cancer, its stage, and the patient's condition are some of the variables that influence the treatment option. The cost of cancer care in Canada, including diagnosis, treatment, and supportive care, is heavily subsidized by both the public and commercial insurance sectors.

canada oncology therapeutics market analysis

Market Dynamics

Market Growth Drivers

Cancer incidence is predicted to rise in Canada due to the country's ageing population as well as lifestyle choices like smoking and obesity. The need for oncology treatments will increase as a result. Oncology medicines have been developed as a result of considerable developments in cancer research and development, which have led to the creation of fresh, cutting-edge treatments for the disease. Patients now have access to more potent therapies, which is fuelling market expansion. Government funding and initiatives: To support cancer research and provide access to oncology treatments, the Canadian government has launched a number of financing and programme initiatives. This includes initiatives like the Pan-Canadian Oncology Drug Review and the Canadian Cancer Research Alliance. More public awareness and screening programmes are resulting in early diagnosis and treatment of numerous malignancies, including breast and colorectal cancer. As more patients are identified and treated as having cancer, this is an increasing demand for oncology treatments. The oncology market is expanding as a result of technological developments like precision medicine and immunotherapy. Better outcomes for patients are being achieved because of these developments, which enable more individualised and focused treatments.

Market Restraints

The regulatory procedure to introduce new oncology treatments to the market can be difficult and drawn out. This can hinder the introduction of fresh treatments, which might slow the expansion of the market. Once the patents on several oncology medicines expire, biosimilars and generic copies of the medications might become accessible. Increased pricing pressure and competition as a result could have an adverse effect on the market expansion. Oncology medicines may have serious adverse effects, which may reduce patient quality of life and force patients to stop receiving their prescribed treatments. This may restrict the market for some treatments, particularly those that have serious adverse effects.

Competitive Landscape

Key Players

Sanofi
Bristol-Myers & Squibb
Pfizer
AstraZeneca
Celgene Corporation
J&J
Novartis

Healthcare Policies and Regulatory Landscape

Health Canada's HPFB is the national authority that regulates, evaluates and monitors the safety, efficacy, and quality of therapeutic and diagnostic products available to Canadians. These products include drugs, medical devices, disinfectants and sanitisers with disinfectant claims. Public insurance: In Canada, the majority of cancer treatments, such as chemotherapy, radiation therapy, surgery, and supportive care, are covered by public insurance. The provincial or territorial healthcare system normally pays the costs of these procedures. Many Canadians also have private health insurance, either via their employers or on their own. Private insurance plans might offer extra cancer treatment coverage, such as for travel to specialised cancer centres for treatment or for newer, more expensive cancer treatments. Despite the fact that the majority of cancer treatments are covered by public or private insurance policies, some procedures or services, such as prescription drugs or complementary therapies, may still be paid for out-of-pocket by the patient. Depending on the patient's unique insurance coverage and the region or territory, these expenses can vary significantly.

Notable Recent Deals

The largest M&A deal in the Canadian Healthcare sector, with a value of $2,260.0 million and completion on August 23, 2021, was secured between Pfizer Inc. and Trillium Therapeutics Inc. GlaxoSmithKline plc and Sierra Oncology Inc. had the second-largest agreement, and Boston Scientific Corp. and Baylis Medical Company Inc. had the third-largest deal. Deals between Boston Scientific Corp. and Baylis Medical Company Inc. and GSK plc and Sierra Oncology Inc. were valued at $1,900.0 million and $1,750.0 million, respectively. The fourth-largest contract, worth $662.6 million, involved Shoppers Drug Store Inc. and LifeMark Health, while the fifth-largest deal, worth $451.8 million, involved Power Financial Corporation and Great-West Lifeco Inc.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Canada Oncology Therapeutics Segmentation

By Application (Revenue, USD Billion):

Blood Cancer
?Colorectal Cancer
Gastrointestinal Cancer
Gynaecologic Cancer
Breast Cancer
Lung Cancer
Prostate Cancer
Others

By Drugs (Revenue, USD Billion):

Revlimid
Avastin
Herceptin
Rituxan
Opdivo
Gleevec
Velcade
Imbruvica
Ibrance
Zytiga
Alimta
Xtandi
Tarceva
Perjeta
Temodar
Others

By Therapy (Revenue, USD Billion):

Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Others

By Route of Administration (Revenue, USD Billion):

Oral
Parenteral
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.